Lupin 2024

Aurobindo gets FDA nod for eletriptan hydrobromide tablets

Print Friendly, PDF & Email

EAST WINDSOR, N.J. — Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for eletriptan hydrobromide tablets, 20 mg and 40 mg. Aurobindo’s eletriptan hydrobromide tablets are an AB-rated generic equivalent to the reference listed drug, Pfizer’s RELPAX.

Eletriptan hydrobromide is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults.
Eletriptan hydrobromide tablets has an estimated market size of $108M for the twelve months ending November 2018 according to IMS.


ECRM_06-01-22


Comments are closed.

Centrum 7/6  banner